Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
FNGO MicroSectors� FANG+� Index 2X Leveraged ETN
VIVC Vivic Corp
LAD Lithia Motors Inc
SBUX Starbucks Corp
HYLN Hyliion Holdings Corp
NIO NIO Inc
F Ford Motor Co
GM General Motors Co
PG Procter & Gamble Co
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Closing Price
$58.15
Day's Change
-0.38 (-0.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
58.58
Day's Low
57.18
Volume
(Average)
Volume:
11,871,686

10-day average volume:
12,568,205
11,871,686

(IMMU) Alert: Johnson Fistel Investigates Proposed Sale of Immunomedics; Is $88 a Fair Price?

9:46 pm ET September 20, 2020 (PR Newswire) Print

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immunomedics Inc. (NASDAQ: IMMU) ("Immunomedics" or the "Company") breached their fiduciary duties in connection with the proposed sale of the Company to Gilead Sciences, Inc.

On September 13, 2020, Immunomedics announced that it had entered into a definitive merger agreement with Gilead. Under the terms of the acquisition agreement, the Company's shareholders will receive $88 per share in cash.

The investigation concerns whether the Immunomedics board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Immunomedics shares of common stock.

If you are a shareholder of Immunomedics and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:Johnson Fistel, LLPJim Baker, 619-814-4471 jimb@johnsonfistel.com

[Click here to join this action]

https://c212.net/c/img/favicon.png?sn=PH30692&sd=2020-09-20

View original content:http://www.prnewswire.com/news-releases/immu-alert-johnson-fistel-investigates-proposed-sale-of-immunomedics-is-88-a-fair-price-301134419.html

SOURCE Johnson Fistel, LLP

https://rt.prnewswire.com/rt.gif?NewsItemId=PH30692&Transmission_Id=202009202145PR_NEWS_USPR_____PH30692&DateId=20200920

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.